Patents by Inventor Robert Klimchak

Robert Klimchak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Low toxicity drug-lipid systems
    Publication number: 20020119170
    Abstract: Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in about a 7:3 mole ratio. The lipid complexes contain a bioactive agent, and may be made by a number of procedures, at high drug:lipid ratios. These compositions of high drug:lipid complexes (HDLCs) may be administered to mammals such as humans for the treatment of infections, with substantially equivalent or greater efficacy and reduced drug toxicities as compared to the drugs in their free form. Also disclosed is a novel liposome-loading procedure, which may also be used in the formation of the HDLCs.
    Type: Application
    Filed: April 26, 2002
    Publication date: August 29, 2002
    Inventors: Andrew S. Janoff, Thomas D. Madden, Pieter R. Cullis, John J. Kearns, Anthony G. Durning, Lawrence Boni, Robert P. Lenk, Robert Klimchak, Joel Portnoff
  • Low toxicity drug-lipid systems
    Patent number: 5616334
    Abstract: Methods and compositions are described for nonliposomal lipid complexes in association with toxic hydrophobic drugs such as the polyene antibiotic amphotericin B. Lipid compositions are preferably a combination of the phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) in about a 7:3 mole ratio. The lipid complexes contain a bioactive agent, and may be made by a number of procedures, at high drug:lipid ratios. These compositions of high drug:lipid complexes (HDLCs) may be administered to mammals such as humans for the treatment of infections, with substantially equivalent or greater efficacy and reduced drug toxicities as compared to the drugs in their free form. Also disclosed is a novel liposome-loading procedure, which may also be used in the formation of the HDLCs.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: April 1, 1997
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, Lawrence Boni, Thomas D. Madden, Pieter R. Cullis, Robert P. Lenk, John J. Kearns, Anthony G. Durning, Robert Klimchak, Joel Portnoff